Eglenen-Polat et al., 2024 - Google Patents
A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancerEglenen-Polat et al., 2024
View HTML- Document ID
- 15367813587355622200
- Author
- Eglenen-Polat B
- Kowash R
- Huang H
- Siteni S
- Zhu M
- Chen K
- Bender M
- Mender I
- Stastny V
- Drapkin B
- Raj P
- Minna J
- Xu L
- Shay J
- Akbay E
- Publication year
- Publication venue
- Nature communications
External Links
Snippet
There are few effective treatments for small cell lung cancer (SCLC) underscoring the need for innovative therapeutic approaches. This study focuses on exploiting telomerase, a critical SCLC dependency as a therapeutic target. A prominent characteristic of SCLC is their …
- 206010028980 Neoplasm 0 title abstract description 128
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu et al. | CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint | |
Huang et al. | NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death | |
Jin et al. | CD70, a novel target of CAR T-cell therapy for gliomas | |
Meyer et al. | Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance | |
Aguilera et al. | Reprogramming the immunological microenvironment through radiation and targeting Axl | |
El Khawanky et al. | Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia | |
Ahmed et al. | Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies | |
Hayashi et al. | Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia | |
Yao et al. | B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells | |
US20190077856A1 (en) | Method of treating diseases using kinase modulators | |
Bam et al. | Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease | |
Turrell et al. | Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse | |
López-Guerra et al. | Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells | |
Trefny et al. | Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy | |
Ruiz-Fernandez de Cordoba et al. | Tumor ENPP1 (CD203a)/Haptoglobin axis exploits myeloid-derived suppressor cells to promote post-radiotherapy local recurrence in breast cancer | |
CN111148518A (en) | Methods of modulating regulatory T cells and immune responses using CDK4/6 inhibitors | |
Wang et al. | Using apelin-based synthetic Notch receptors to detect angiogenesis and treat solid tumors | |
Akhand et al. | Pharmacologic inhibition of FGFR modulates the metastatic immune microenvironment and promotes response to immune checkpoint blockade | |
Eglenen-Polat et al. | A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer | |
WO2014190035A2 (en) | Compositions and methods for identification, assessment, prevention, and treatment of cancer using histone h3k27me2 biomarkers and modulators | |
Porter et al. | Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models | |
Vitorino et al. | Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression | |
Sugita et al. | Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia | |
Kim et al. | Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors | |
Wang et al. | TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells |